Welcome to our dedicated page for TriSalus Life Sciences SEC filings (Ticker: TLSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TriSalus Life Sciences, Inc. (Nasdaq: TLSI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. TriSalus identifies itself in these filings as an emerging growth company and an oncology-focused medical technology business built around its Pressure-Enabled Drug Delivery (PEDD) platform and investigational immunotherapy, nelitolimod.
Through Forms 8-K, TriSalus reports material events such as quarterly financial results, business updates, changes in directors, compensation decisions and capital structure actions. Recent 8-K filings describe press releases announcing results for quarters ended June 30 and September 30, 2025, along with revenue performance driven by sales of the TriNav system. Other 8-Ks detail an exchange offer and consent solicitation related to Series A Convertible Preferred Stock, amendments to the certificate of designations, and subsequent conversion of preferred shares into common stock.
These filings also document governance and compensation matters, including director resignations and adjustments to executive base salary and performance-based stock option grants that vest upon achieving specified revenue thresholds. Together, they provide insight into how TriSalus manages its capital structure, aligns management incentives and responds to financing needs while advancing its PEDD-based devices and clinical-stage immunotherapy.
On Stock Titan, SEC documents for TLSI are updated as they are made available through EDGAR. AI-powered tools can help summarize lengthy filings, highlight key sections related to revenue, operating results, capital structure changes and governance items, and make it easier to interpret the implications of each report. This allows users to quickly understand what TriSalus is disclosing about its operations, financial condition and strategic decisions without reading every page in detail.
TriSalus Life Sciences director David J. Matlin converted preferred stock into common shares under a company offer. On July 31, 2025, all 100,000 shares of Series A Preferred Stock held by Matlin were converted into 330,000 shares of common stock.
The conversion followed an exchange offer allowing all preferred holders to receive common shares equal to the liquidation preference of $10.00 per preferred share plus accrued and unpaid dividends through August 10, 2027, divided by a $4.00 conversion price per share. After the conversion, Matlin directly owned 1,271,944 common shares and no remaining preferred shares.
TriSalus Life Sciences, Inc. will hold its 2026 virtual annual stockholder meeting on May 14, 2026 at 10:00 a.m. Eastern Time via live audio webcast at https://www.virtualshareholdermeeting.com/TLSI2026 for holders of record as of March 20, 2026.
Stockholders will vote on four items: electing two Class III directors (Mary Szela and Gary Gordon) to serve until the 2029 meeting, ratifying Grant Thornton LLP as independent auditor for 2026, an advisory “say-on-frequency” vote where the Board recommends a three-year cycle, and an advisory “say-on-pay” vote on 2025 executive compensation.
The proxy explains virtual participation and voting mechanics for registered and beneficial owners, outlines board and committee structure, and details 2025 pay for named executive officers, including total compensation of $4,823,349 for CEO Mary Szela.
TriSalus Life Sciences, Inc. executive Jodi Devlin, Chief of Clinical Operations, reported three transactions in common stock. Across 3,207 shares, stock was sold at prices between $4.09 and $4.13 per share to satisfy tax withholding obligations tied to previously vested restricted stock units. A footnote explains these sales were made solely to cover taxes and were not discretionary. Following the most recent transaction, Devlin directly holds 97,364 shares of TriSalus common stock.
TriSalus Life Sciences Chief of Research Bryan F. Cox reported automatic sales of common stock to cover taxes on vested restricted stock units. Across three trades on March 11, 12 and 16, 2026, a total of 3,184 shares were sold around $4.09–$4.13 per share, leaving him with 163,415 directly held shares. A footnote explains these sales were solely to satisfy tax withholding obligations and were not discretionary.
TriSalus Life Sciences Chief Commercial Officer Richard Marshak reported routine share disposals tied to tax withholding, not discretionary selling. Over three days, he disposed of a total of 3,457 shares of common stock at prices between $4.09 and $4.13 per share. A footnote explains these shares were sold solely to satisfy tax obligations from vesting restricted stock units previously granted to him. After these transactions, Marshak continues to hold 110,397 shares of TriSalus common stock directly, indicating the disposals are small relative to his remaining stake.
TriSalus Life Sciences Chief Regulatory Officer Jennifer Stevens reported routine share sales tied to tax withholding. She sold a total of 3,530 shares of common stock in open-market transactions between March 11 and March 16 at prices around $4.09–$4.13 per share.
According to the disclosure, the shares were sold solely to satisfy tax obligations from vesting restricted stock units and do not represent discretionary sales. After these transactions, she continues to hold 124,110 TriSalus shares directly.
TriSalus Life Sciences CEO and President Mary T. Szela reported routine share dispositions tied to tax withholding, not discretionary selling. On March 17, she disposed of 15,944 shares of common stock at $3.85 per share. On March 11, she disposed of 4,358 shares at $4.13 per share. A footnote explains these shares were sold to satisfy tax obligations from vesting restricted stock units and that the activity does not represent a discretionary sale. After these transactions, she directly holds 752,987 common shares.
TriSalus Life Sciences is an oncology-focused medtech company combining proprietary drug-delivery devices with an investigational immunotherapy, nelitolimod, to treat solid tumors, especially in the liver and pancreas. Its core Pressure-Enabled Drug Delivery (PEDD) platform underpins the FDA‑cleared TriNav Infusion System and a 510(k)‑cleared pancreatic device (PRVI).
TriNav, used mainly in TACE and TARE procedures, has been employed in over 31,000 procedures and generated $45.2 million in 2025 revenue, a 53.4% increase versus the prior year. Clinical and real‑world data show improved tumor targeting, higher drug deposition and reduced complications compared with standard microcatheters. Management estimates a U.S. total addressable PEDD market projected to exceed $2.3 billion annually across liver cancers, pancreatic tumors, fibroids, multinodular goiters, prostate disease and osteoarthritis‑related knee pain.
Nelitolimod, a class C TLR9 agonist acquired from Dynavax, is being tested with PEDD in three Phase 1 PERIO studies in uveal melanoma liver metastases, cholangiocarcinoma, hepatocellular carcinoma and locally advanced pancreatic cancer, with readouts expected in 2026. The company holds a broad patent portfolio extending into the 2030s, manufactures TriNav in Colorado, and benefits from permanent CMS reimbursement codes C9797 and C8004 that support outpatient and ambulatory use.
TriSalus Life Sciences reported strong growth for 2025 but remained unprofitable. Revenue from the TriNav system reached $45.2 million for the year, up 53% from 2024, with fourth quarter revenue of $13.2 million, a 60% year-over-year increase and 14% sequential growth.
Full-year gross profit rose to $38.2 million, though gross margin edged down to 84.6%, reflecting launch-related manufacturing inefficiencies. Operating loss narrowed to $26.9 million, and adjusted EBITDA loss improved to $17.2 million. Net loss attributable to common stockholders expanded to $69.7 million, mainly due to preferred stock conversion-related items.
Cash and cash equivalents were $20.4 million as of December 31, 2025, and subsequent to year-end the company raised $46 million in gross proceeds via a public offering. Management reaffirmed 2026 revenue guidance of $60–62 million and highlighted continued commercial adoption of TriNav, higher gross margins in Q4 2025, and ongoing investments in clinical studies and new PEDD-based products.